Now showing items 1-2 of 2

    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, N D; de Bono, J S; Spears, M R; Clarke, NW; Mason, M D; Dearnaley, D P; Ritchie, A W S; Amos, C L; Gilson, C; Jones, R J; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, W R; Gillessen, S; Parker, C C; Russell, J M; Berthold, D R; Brawley, C; Adab, F; Aung, San; Birtle, A J; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, P J; Lester, J F; Malik, Z I; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, N N; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, M K B; Sydes, M R (New England Journal of Medicine, 2017-07)
      Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, ...
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, N D; Sydes, M R; Clarke, N W; Mason, M D; Dearnaley, D P; Spears, M R; Ritchie, A W S; Parker, C C; Russell, J M; Attard, G; de Bono, J; Cross, W; Jones, R J; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, A J; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, J D; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, D B; O'Sullivan, J M; Parikh, Oi; Peedell, C; Protheroe, A; Robinson, A J; Srihari, N; Srinivasan, Rajaguru; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, M K B (Elsevier, 2015-12-21)
      Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, ...